Life Sciences

Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge
13 January 2022

Dermala Awarded Grand Prize in Inaugural Colgate Connect Challenge

DERMALA, a consumer dermatology company that develops novel treatments for chronic skin conditions, announces the brand's Grand Prize recognition in the global pitch...

Read more
MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
3 November 2021

MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris

MaaT Pharma S.A. ("MaaT Pharma" or the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome2-based ecosystem therapies dedicated to...

Read the press release
Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder
27 October 2021

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, today announced that the...

Read the press release
BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
13 October 2021

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target...

Read the press release
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
13 October 2021

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25...

Read more
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
5 October 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...

Read the press release
A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council
2 September 2021

A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council

A crucial step has been taken by Belgian company A-Mansia Biotech, a co-spin-off of Wageningen University and UCLouvain. The European Food Safety Authority (EFSA) considers the...

Read the press release
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
16 June 2021

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting...

Read the press release
Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
15 June 2021

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression

Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...

Read the press release